MCK vs MDLN: How McKesson Corporation and Medline Compare (2026)
Last updated August 2026
Short answer
MCK and MDLN are similarly sized, but MCK trades noticeably cheaper on forward earnings (17.00x vs 22.38x): the market is paying up for MDLN's profile and pricing MCK more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
MCK vs MDLN: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MCK | MDLN | What it tells you |
|---|---|---|---|
| Forward P/E | 17.00 | 22.38 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 22.32 | 36.67 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Price vs 52-week range | 61% of range | 21% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: MCK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how MCK and MDLN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MCK and MDLN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MCK and MDLN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does McKesson Corporation (MCK) do?
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.
What does Medline (MDLN) do?
Medline makes and distributes the unglamorous consumables that hospitals, surgery centers, physician offices, and nursing homes go through every single day: gloves, gowns, surgical kits, wound care, incontinence products, exam-room supplies, and diagnostics. It reports in two segments. Medline Brand covers products the company manufactures and sells under its own label (surgical solutions, front-line care, laboratory and diagnostics), and it carries the better margin. Supply Chain Solutions distributes third-party manufacturers' brands and runs the prime-vendor logistics contracts that put Medline trucks on a health system's loading dock several times a week. Roughly 90 percent of revenue is domestic. The company employs about 45,000 people and is headquartered in Northfield, Illinois.
MCK vs MDLN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.
- MDLN drivers: Prime-vendor contracts in Supply Chain Solutions; Mix shift toward Medline Brand products.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. For MDLN, the clearest near-term risk is regulatory.
MCK or MDLN: which should you pick?
MCK vs MDLN: the full fundamentals
MCK. All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.
MDLN. The trailing P/E near 46 times looks expensive until you notice that trailing net income is depressed by the Tracy fire, quality remediation spend, and post-IPO charges, which is why the market watches adjusted EBITDA instead. On enterprise value of roughly $58 billion against full-year adjusted EBITDA guidance of $3.3 to $3.4 billion, the multiple sits around 17 times. That guidance was cut from $3.5 to $3.6 billion in the August 2026 release even as organic growth guidance went up to 9 to 10 percent, and the shares fell roughly 13 percent on the day. Medline does not pay a dividend.
Headline figures (approximate, Jul 2026): MCK shows revenue (fy2026) ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live), segment profit mix North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate), margin profile Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins, earnings trend Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures); MDLN shows revenue (ttm) ~$29.9B, up ~12%, q2 2026 net sales ~$7.7B, up ~11.6%, gross margin (ttm) ~26%, net income (ttm) ~$693M, down ~45%.
The bottom line: MCK vs MDLN
MCK and MDLN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MCK and MDLN exposure against your real portfolio. It is not an investment adviser.
Wondering how MCK or MDLN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in McKesson Corporation with AI
Connect the broker you already use and ask Walnut's AI how MCK fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between MCK and MDLN?
+
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. Medline makes and distributes the unglamorous consumables that hospitals, surgery centers, physician offices, and nursing homes go through every single day: gloves, gowns, surgical kits, wound care, incontinence products, exam-room supplies, and diagnostics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MCK or MDLN the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MCK or MDLN?
+
On forward P/E (as of August 2026), MCK trades at 17.00x and MDLN at 22.38x, so MCK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MCK and MDLN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MCK vs MDLN?
+
MCK: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation and on integrating oncology and specialty acquisitions adds transition risk on top of the steady core. MDLN: The clearest near-term risk is regulatory. As of late June 2026 Medline had received three FDA warning letters covering facilities in Northfield, Illinois, Glens Falls, New York, and Waukegan, Illinois, with the Waukegan letter calling certain drug products adulterated after Bacillus cereus turned up in finished product samples on nine separate occasions between June 2023 and August 2025. Remediation costs money, can interrupt supply from specific plants, and invites further inspection. Second, the net margin is thin enough (roughly 2 percent trailing) that operational shocks like the Tracy distribution center fire, which cost about $336 million before insurance in the first half with another $50 million to $100 million expected in the second, dominate reported earnings even when the underlying business is fine. Third, tariffs and freight costs pass through a global sourcing base with a lag, and the second quarter figure was flattered by about $243 million of tariff refunds that will not repeat. Fourth, hospital group purchasing organizations negotiate hard and Cardinal Health, McKesson, and Owens & Minor all want the same shelf space. Finally, Blackstone, Carlyle, and Hellman & Friedman still hold a large block and have already run one $3.6 billion secondary at $41 per share, so supply overhang is a live factor in how the shares trade. Several shareholder law firms announced investigations following the FDA disclosure.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MCK or MDLN; figures are approximate and dated (as of August 2026). Verify current data before investing.